Ultragenyx To Present GTX-102 Angelman Syndrome Program Update At The ASF Family Conference And Research Symposium On Wednesday, July 24, 2024

7/24/24 8:09:57 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RARE alert in real time by email

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wednesday, July 24, at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.

Get the next $RARE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RARE

Date	Price Target	Rating	Analyst
6/6/2024	$56.00 → $67.00	Neutral → Buy	Goldman
4/22/2024	$77.00	Outperform	RBC Capital Mkts
12/8/2023	$72.00	Overweight	Wells Fargo
6/14/2023	$96.00	Outperform	Credit Suisse
6/6/2023	$60.00 → $80.00	In-line → Outperform	Evercore ISI
4/26/2023	$114.00	Overweight	Cantor Fitzgerald
1/18/2023	$90.00	Buy	Canaccord Genuity
12/30/2022	$82.00	Buy	H.C. Wainwright

More analyst ratings

$RARE
Press Releases

Fastest customizable press release news feed in the world

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company's common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4
11/20/24 4:30:00 PM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by end-of-year NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, that will be presented at the 2024 Foundation for Angelman Syndrome Therapeutics (FAST) Global Science Summit in Orlando, Florida. "Cognition is the building block for the development and ascertainment of many new skills across a range of the
11/9/24 10:30:00 AM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa) NOVATO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious r
11/5/24 4:01:00 PM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care

$RARE
Financials

Live finance-specific insights

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa) NOVATO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious r
11/5/24 4:01:00 PM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 5, 2024, to discuss its financial results and corporate update for the quarter ending September 30, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharma
10/29/24 4:05:00 PM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, August 1, 2024, to discuss its financial results and corporate update for the quarter ending June 30, 2024. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmace
7/25/24 4:05:00 PM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care

$RARE
Leadership Updates

Live Leadership Updates

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. "Howard is joining Ultragenyx and its leadership team during a pivotal period as our robust late-stage pipeline is maturing and we are preparing for the next phase of company growth," said Emil D. Kakkis, M.D.,
7/12/23 8:00:00 AM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as Ultragenyx's chief medical officer for gene therapy and inborn errors of metabolism. "Eric has extensive expertise in the development and execution of clinical development programs for rare genetic disorders and has been a driving force for our entire gene therapy pipeline," said Emil D. Kakkis, M.D., Ph.D., chief executive of
3/14/23 8:30:00 AM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company's Board of Directors. Dr. Ray will serve on the Board's Research and Development Committee. "Dr. Ray brings to our Board of Directors decades of global experience as a physician researcher, biopharmaceutical executive, and champion for patient access to innovative treatments," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. "His expertise
4/22/22 8:00:00 AM ET
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care

Ultragenyx To Present GTX-102 Angelman Syndrome Program Update At The ASF Family Conference And Research Symposium On Wednesday, July 24, 2024

Chat with this insight

Recent Analyst Ratings for $RARE

$RARE SEC Filings

Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

$RARE Market Insights

Live Market Insights

Ultragenyx To Present GTX-102 Angelman Syndrome Program Update At The ASF Family Conference And Research Symposium On Wednesday, July 24, 2024

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Maintains $111 Price Target

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

$RARE Press Releases

Fastest customizable press release news feed in the world

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

$RARE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ultragenyx Pharma upgraded by Goldman with a new price target

RBC Capital Mkts initiated coverage on Ultragenyx Pharma with a new price target

Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

$RARE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Horn Howard sold $393,853 worth of shares (7,465 units at $52.76), decreasing direct ownership by 7% to 92,301 units (SEC Form 4)

SVP, Chief Accounting Officer Huizenga Theodore Alan was granted 700 shares, increasing direct ownership by 2% to 42,251 units (SEC Form 4)

President & CEO Kakkis Emil D sold $1,117,000 worth of shares (20,000 units at $55.85) (SEC Form 4)

$RARE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

$RARE Financials

Live finance-specific insights

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

$RARE Leadership Updates

Live Leadership Updates

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

Recent Analyst Ratings for
$RARE

$RARE
SEC Filings

$RARE
Market Insights

$RARE
Press Releases

$RARE
Analyst Ratings

$RARE
Insider Trading

$RARE
Large Ownership Changes

$RARE
Financials

$RARE
Leadership Updates